Diagnostic Innovations

Optimal Treatments in Oncology

Patient Benefit through latest Technology

Since patients are individual and unique, their illnesses are also very different. No oncological findings are equal to each other. Therefore, specific diagnostic procedures are urgently needed to reveal individual characteristics of the disease and thus enable optimal treatment.

Medical Technologies made in Germany

Optimal Treatment using latest Diagnostic Procedures

Individual cancer treatment is the major goal of personalized medicine today. The GILUPI CellCollector® - a technology platform developed and manufactured in Germany - supports individual treatment through innovative cancer diagnostics. The GILUPI technology has been extensively tested in over 10,000 patient applications and has been certified and approved for diagnostics in the EU and China for many years.

Contact us !

Liquid Biopsy trough Circulating Tumor Cells

Innovative Sample Material

The analysis of tissue biopsies has been state of the art for many years. However, it is an invasive procedure and cannot be carried out on all tumors or at every point in the course of the disease. The so-called liquid biopsy is an approach that uses the patient's bloodstream as a source to obtain circulating tumor cells (CTCs), which can be used as "real-time markers" at any time without bigger burden on the patient. The enrichment of these circulating tumor cells can circumvent the limitations of a tissue biopsy and help to enable alternative treatment for the patient through innovative diagnostics.

Novel Technology Platform

Enrichment of Circulating Cells in the Bloodstream

The GILUPI technology delivers viable cells that today can only be obtained in sufficient numbers through biopsies. However, biopsies are invasive and therefore associated with risks for the patient and are often not available due to a lack of suitable tissue (e.g. after surgery of the primary tumor). The innovative method enables a breakthrough in the currently impending limits of tissue biopsy and also in the enrichment of circulating tumor cells from blood samples. The GILUPI platform is the only method that enriches target cells directly in the bloodstream (in vivo) and not from a volume-limited blood sample. This means that the probability of gaining access to the circulating cells, which are very rare, is significantly increased.

Certified Medical Technology

The GILUPI CellCollector®

The medical device is a thin medical stainless steel wire that contains a specially coated 2cm long tip. The tip consists of various thin layers of coating that ensures specific binding of target cells. The coating also prevents other blood components from being bound. A standard indwelling venous cannula is used for insertion into the patient's arm vein - similar to an infusion cannula. The 2cm tip of the GILUPI CellCollector® protrudes into the patient's blood flow and the circulating tumor cells are specifically bound to the coated surface of the medical device. After an application time of 30 minutes, the isolated cells can then be used for any kind of diagnostic procedure.

In Practice

From Enrichment to Result Report

The use of the GILUPI CellCollector® is comparable to a standard blooddraw. The GILUPI CellCollector® is introduced into the bloodstream by using an arm vein in the crook of the elbow. After 30 minutes of application, it is removed from the vein and the cells bound to the tip can be examined. The requesting physician decides which diagnostic procedures will be performed after cell enrichment. Examples for the downstream process are cell staining (e.g. immunofluorescence staining) or molecular analyzes (e.g. PCR, in situ padlock probe technology, sequencing or gene expression analysis). Since the enriched cells are viable cells, they can also be cultured (reproduction in the cell culture laboratory).


Application & Post Treatment

For application of the GILUPI CellCollector®, a standard 20G indwelling venous cannula (cannulas for infusions in children) is used as access into the arm vein of the elbow. The GILUPI CellCollector® is introduced into the bloodstream through this indwelling cannula. After 30 minutes of use, the GILUPI CellCollector® is removed from the arm vein and the cells bound to the tip are available for further analysis. The follow-up treatment of the medical device depends on the diagnostic procedure used in the downstream process. Our application video explains the application and post-treatment for later cell staining (e.g. immunofluorescence staining).

Various possibilities of Application

Areas of Application

The GILUPI CellCollector® is a product for enrichment of EpCAM-positive circulating tumor cells from the bloodstream. A surface protein that occurs on a variety of tumor cells. The product has been used in more than 10,000 clinical applications across a wide range of cancer entities, including:

  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • Head and Neck Tumors

GILUPI Insights and More